When treated with platinum-based chemotherapy, NSCLC patients with BRAF V600E mutation had a tendency of shorter progression-free survival (PFS) than those with BRAF non-V600E mutations, and the clinical outcomes between patients with BRAF mutation-positive and wild-types were similar, suggesting that BRAF mutations were not sensitive to chemotherapy. This evidence concerns the gene BRAF and non-small cell lung carcinoma.